Evidence map›Paper›PMID 35389568›Full record

ArticleClinical and translational medicine2022

Red-shifted optogenetics comes to the spotlight.

Tianlu Wang, Siyao Liu, Yun Huang, Yubin Zhou

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Optogenetic engineering for ion channel modulation.Current opinion in chemical biology · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Red-shifted optogenetics comes to the spotlight.Clinical and translational medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tianlu WangCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, USA.
Siyao LiuCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, USA.
Yun HuangCenter for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, USA.
Yubin ZhouCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, USA.

Funding

NanoOptogenetic immunotherapy for B cell lymphomaR01CA232017 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HAN, GANG, ZHOU, YUBIN · 2019 to 2023
$2.2M
TET-mediated epigenetic regulation in cardiac development.R01HL134780 · NHLBI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI HUANG, YUN · 2018 to 2022
$1.9M
NCI NIH HHS R01 CA232017NHLBI NIH HHS R01 HL134780
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

LightOptogenetics

Identifiers

PMID35389568
PMCPMC8989019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.